| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer DP Petrylak, CM Tangen, MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, ... New England Journal of Medicine 351 (15), 1513-1520, 2004 | 4679 | 2004 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer CJ Sweeney, YH Chen, M Carducci, G Liu, DF Jarrard, M Eisenberger, ... New England Journal of Medicine 373 (8), 737-746, 2015 | 3002 | 2015 |
| Characterization of human plasma-derived exosomal RNAs by deep sequencing X Huang, T Yuan, M Tschannen, Z Sun, H Jacob, M Du, M Liang, ... BMC genomics 14, 1-14, 2013 | 1198 | 2013 |
| Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ... Journal of Clinical Oncology 36 (11), 1080-1087, 2018 | 1028 | 2018 |
| Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer X Huang, T Yuan, M Liang, M Du, S Xia, R Dittmar, D Wang, W See, ... European urology 67 (1), 33-41, 2015 | 685 | 2015 |
| Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial NB Haas, J Manola, RG Uzzo, KT Flaherty, CG Wood, C Kane, M Jewett, ... The Lancet 387 (10032), 2008-2016, 2016 | 682 | 2016 |
| Evaluation and management of patients with heart disease and cancer: cardio-oncology J Herrmann, A Lerman, NP Sandhu, HR Villarraga, SL Mulvagh, M Kohli Mayo Clinic Proceedings 89 (9), 1287-1306, 2014 | 521 | 2014 |
| Nanoparticles for combination drug therapy L Ma, M Kohli, A Smith ACS nano 7 (11), 9518-9525, 2013 | 369 | 2013 |
| Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 DP Petrylak, DP Ankerst, CS Jiang, CM Tangen, MHA Hussain, ... Journal of the National Cancer Institute 98 (8), 516-521, 2006 | 328 | 2006 |
| Plasma extracellular RNA profiles in healthy and cancer patients T Yuan, X Huang, M Woodcock, M Du, R Dittmar, Y Wang, S Tsai, M Kohli, ... Scientific reports 6 (1), 19413, 2016 | 295 | 2016 |
| Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III … C Sweeney, YH Chen, MA Carducci, G Liu, DF Jarrard, MA Eisenberger, ... Journal of Clinical Oncology 32 (15_suppl), LBA2-LBA2, 2014 | 268 | 2014 |
| Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies G Gravis, JM Boher, YH Chen, G Liu, K Fizazi, MA Carducci, S Oudard, ... European urology 73 (6), 847-855, 2018 | 250 | 2018 |
| Measure transcript integrity using RNA-seq data L Wang, J Nie, H Sicotte, Y Li, JE Eckel-Passow, S Dasari, PT Vedell, ... BMC bioinformatics 17, 1-16, 2016 | 232 | 2016 |
| Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression X Jin, D Ding, Y Yan, H Li, B Wang, L Ma, Z Ye, T Ma, Q Wu, ... Molecular cell 73 (1), 22-35. e6, 2019 | 219 | 2019 |
| miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1 Y Wang, R Lieberman, J Pan, Q Zhang, M Du, P Zhang, M Nevalainen, ... Molecular cancer 15, 1-11, 2016 | 143 | 2016 |
| HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study JWD Hearn, G AbuAli, CA Reichard, CA Reddy, C Magi-Galluzzi, ... The Lancet Oncology 17 (10), 1435-1444, 2016 | 142 | 2016 |
| Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance M Kohli, Y Ho, DW Hillman, JL Van Etten, C Henzler, R Yang, JM Sperger, ... Clinical Cancer Research 23 (16), 4704-4715, 2017 | 141 | 2017 |
| Activation of P-TEFb by androgen receptor-regulated enhancer RNAs in castration-resistant prostate cancer Y Zhao, L Wang, S Ren, L Wang, PR Blackburn, MS McNulty, X Gao, ... Cell reports 15 (3), 599-610, 2016 | 127 | 2016 |
| Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma PD Grivas, S Daignault, ST Tagawa, DM Nanus, WM Stadler, R Dreicer, ... Cancer 120 (5), 692-701, 2014 | 115 | 2014 |
| Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease V Kaushal, P Mukunyadzi, RA Dennis, ER Siegel, DE Johnson, M Kohli Clinical cancer research 11 (2), 584-593, 2005 | 112 | 2005 |
